Erasca, Inc. 2023 Form 10-K Summary
Business context and reporting period
Erasca is a clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers. Its clinical-stage pipeline includes naporafenib, an oral pan-RAF inhibitor; ERAS-007, an oral ERK1/2 inhibitor; and ERAS-801, a CNS-penetrant EGFR inhibitor. The filing covers the fiscal year ended December 31, 2023; it does not provide a separate standalone fourth-quarter financial presentation.
The company has no approved products and generated no product revenue. It is classified as an emerging growth company and smaller reporting company.
Financial performance and liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $103.8 million | $112.5 million | Down $8.6 million |
| In-process R&D expense | $0 | $102.0 million | Down $102.0 million |
| General and administrative expense | $37.7 million | $33.0 million | Up $4.7 million |
| Total operating expenses | $141.5 million | $247.5 million | Down $105.9 million |
| Loss from operations | $141.5 million | $247.5 million | Improved by $105.9 million |
| Other income, net | $16.5 million | $4.6 million | Up $11.8 million |
| Net loss | $125.0 million | $242.8 million | Improved by $117.8 million |
| Basic and diluted loss per share | $0.83 loss | $1.99 loss | Improved |
| Net cash used in operating activities | $101.2 million | $103.3 million | Improved by $2.0 million |
| Cash, cash equivalents and marketable securities | $322.0 million | Approximately $435.6 million | Decreased |
There is no meaningful revenue or profit margin because the company has no commercial products and remains loss-making. Stock-based compensation was $26.2 million in 2023, compared with $20.1 million in 2022.
Cash, cash equivalents and restricted cash totaled $93.5 million at year-end, while marketable securities totaled $228.9 million. Management believes available cash, cash equivalents and marketable securities will fund operations into the first half of 2026, based on current plans. The filing states that additional capital will likely be required thereafter, or sooner if development spending increases.
The filing does not disclose conventional funded debt. Liabilities primarily comprise operating lease obligations and accounts payable and accrued liabilities. Total operating lease commitments were $80.5 million, including approximately $8.8 million due in 2024.
Material changes versus the prior comparable period
- Net loss declined substantially because 2022 included $102.0 million of in-process R&D expense, principally related to the Novartis naporafenib license and a Katmai milestone.
- Research and development expense declined 8% to $103.8 million, primarily because of pipeline prioritization and lower clinical, preclinical and outsourced costs. These reductions were partly offset by higher personnel, facilities and stock-based compensation costs.
- General and administrative expense increased 14% to $37.7 million, primarily due to higher stock-based compensation, personnel and facilities costs.
- Interest income increased to $16.7 million from $4.9 million because of higher cash and investment yields.
- Cash used in investing activities increased to $91.2 million, reflecting increased purchases of marketable securities and a $20.0 million cash payment associated with in-process R&D.
- No shares were sold under the company’s $200 million at-the-market facility through December 31, 2023. Financing cash flow was only $1.3 million in 2023, compared with $98.1 million in 2022 from the underwritten offering.
Development outlook, commentary and unusual items
- Naporafenib: The company planned to initiate the randomized Phase 3 SEACRAFT-2 trial in the first half of 2024 for post-immunotherapy NRAS-mutated melanoma. SEACRAFT-1, a Phase 1b trial in RAS Q61X solid tumors, dosed its first patient in August 2023, with a combination data readout anticipated between the second and fourth quarters of 2024.
- The FDA granted Fast Track Designation to naporafenib plus trametinib for previously treated or intolerant NRAS-mutated melanoma.
- ERAS-007: The company deprioritized the ERAS-007 plus ERAS-601 combination, the ERAS-007 plus osimertinib combination, and an ERAS-007 plus palbociclib sub-study because of safety or insufficient efficacy. It continued HERKULES-3 development of ERAS-007 with encorafenib and cetuximab in BRAF-mutated colorectal cancer and expected updated data in the first half of 2024.
- ERAS-801: The FDA granted Fast Track Designation and Orphan Drug Designation for EGFR-altered glioblastoma or malignant glioma. The maximum tolerated dose was identified in November 2023, with Phase 1 monotherapy data expected in 2024.
- ERAS-3490, a CNS-penetrant KRAS G12C inhibitor, was deprioritized because of the increasingly competitive market. The FLAGSHP-1 combination trial of ERAS-601 and cetuximab was also deprioritized despite confirmed responses, because preliminary data did not justify further development in the tested indications.
- License obligations remain material. The Novartis agreement includes up to $80 million of regulatory milestones, up to $200 million of sales milestones and low-single-digit royalties. Other agreements include additional development and commercial milestones and royalties. No contingent milestones were accrued at year-end because the conditions were not considered probable or estimable.
- In January 2024, Erasca agreed to sublease approximately 10,000 square feet of San Diego office space for three years. It also granted options covering 9.8 million shares to employees and directors in January and February 2024 at a weighted-average exercise price of $1.71 per share.
Principal risks and contingencies
- The company has a limited operating history, an accumulated deficit of $606.0 million, no product revenue and expects significant additional losses.
- Clinical development, regulatory approval and commercialization are uncertain. Positive early or preliminary data may not predict results in later or randomized trials.
- Combination regimens may increase toxicity. Reported risks include rash, gastrointestinal events, creatine phosphokinase increases, ocular toxicity, neutropenia and elevated AST, depending on the program and regimen.
- Additional financing may be required and could dilute existing stockholders, impose debt covenants or require the company to relinquish rights to programs.
- The company relies on third parties for clinical trials, manufacturing, packaging, distribution and certain research activities, creating execution, quality, supply and timing risks.
- Competition is intense, particularly in RAS/MAPK and KRAS-targeted oncology. Larger competitors may have greater financial, clinical, manufacturing and commercial resources.
- Patent rights are subject to prosecution, validity, enforcement, licensing and freedom-to-operate risks. The company disclosed a potential foreign-filing-license issue involving an Indian ERAS-007 patent application.
- Regulatory designations such as Fast Track and Orphan Drug Designation do not guarantee approval or commercialization.
- Operating lease commitments, stock-based compensation, potential license milestones and future clinical costs may materially affect liquidity.
- The company reported no material cybersecurity incident to date and assessed disclosure controls and internal control over financial reporting as effective as of December 31, 2023; however, cybersecurity, privacy and third-party system risks remain.
Most important facts for investors to verify
- Whether SEACRAFT-2 was initiated on schedule and whether its final design remains registration-enabling.
- Updated efficacy, durability and safety data for naporafenib plus trametinib in NRAS-mutated melanoma and RAS Q61X tumors.
- HERKULES-3 data for ERAS-007 plus encorafenib and cetuximab, including confirmation of the preliminary response data.
- ERAS-801 Phase 1 data, recommended Phase 2 dose and evidence of activity in EGFR-altered glioblastoma.
- The company’s actual cash burn and remaining runway as Phase 3 and other clinical programs expand.
- Potential equity issuance under the $200 million at-the-market facility and dilution from outstanding and newly granted equity awards.
- Timing and probability of contingent regulatory, development and sales milestones under licensing agreements.
- Whether pipeline deprioritizations continue and how capital is being reallocated among naporafenib, ERAS-007 and ERAS-801.